A Comparative Analysis of Cardiovascular Events Associated With Acalabrutinib Versus Ibrutinib in Chronic Lymphocytic Leukemia: Insights From a Global Federated Network
Pharmacology Research & Perspectives · 2025
DOI: 10.1002/prp2.70113 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Pharmacology Research & Perspectives, 2025. Verfasst von Abdulrahman Majrashi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverp…. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Benzamides, Piperidines, Adenine. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Jazan University.
Abstract (Originalsprache)
Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in adults, characterized by the accumulation of dysfunctional lymphocytes. Ibrutinib, a first‐generation Bruton tyrosine kinase (BTK) inhibitor, has significantly improved CLL treatment but is associated with adverse cardiovascular events such as atrial fibrillation (AF) and hypertension (HTN). Second‐generation BTK inhibitors (BTKi) such as acalabrutinib were developed to have greater selectivity for BTK to reduce off‐target effects and improve safety. Comparative real‐world data between ibrutinib and second‐generation BTKi are limited. This study analyzed data from the TriNetX Global Collaborative Network to compare cardiovascular outcomes in CLL patients who received ibrutinib or acalabrutinib. The two groups were well‐balanced using propensity score matching. The outcomes examined included new‐onset AF, HTN, reported heart failure, ventricular arrhythmias, bleeding, and all‐cause mortality. The incidence of AF/flutter was lower for acalabrutinib compared to ibrutinib [5.8% vs. 11.7%; HR 0.59 (95% CI 0.43–0.83); p = 0.002]. The incidence of HTN was also lower in the acalabrutinib cohort [15% vs. 26.3%; HR 0.65 (95% CI 0.53–0.81); p < 0.05]. The incidence of heart failure, ventricular arrhythmia, bleeding events, or all‐cause mortality did not differ after 3 years of treatment with acalabrutinib or ibrutinib, respectively. Our findings indicate that acalabrutinib has a more favorable cardiovascular toxicity profile compared to ibrutinib; therefore, validating the ELEVATE‐RR trial in a real‐world setting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverpool, UK.
- Department of Emergency Medical Services, College of Nursing & Health Sciences, Jazan University, Jazan, Saudi Arabia.
- Department of Cardiovascular and Metabolic Medicine, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK.
- Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, UK.
- Department of Health Data Science, University of Liverpool, Liverpool, UK.
- Department of Clinical Medicine, Danish Centre for Health Services Research, Aalborg University, Aalborg, Denmark.
ORCID-Profile: Abdulrahman Majrashi
Förderung
- Jazan University
Zitieren
APA
Majrashi, A., Gue, Y. X., Shantsila, A., Williams, S., Smith, C. T., Lip, G. Y. H., & Pettitt, A. R. (2025). A Comparative Analysis of Cardiovascular Events Associated With Acalabrutinib Versus Ibrutinib in Chronic Lymphocytic Leukemia: Insights From a Global Federated Network. Pharmacology Research & Perspectives. https://doi.org/10.1002/prp2.70113
Vancouver
Majrashi A, Gue YX, Shantsila A, Williams S, Smith CT, Lip GYH, et al. A Comparative Analysis of Cardiovascular Events Associated With Acalabrutinib Versus Ibrutinib in Chronic Lymphocytic Leukemia: Insights From a Global Federated Network. Pharmacology Research & Perspectives. 2025. doi:10.1002/prp2.70113
BibTeX
@article{Majrashi2025,
author = {Majrashi, Abdulrahman and Gue, Ying X and Shantsila, Alena and Williams, Stella and Smith, Catrin Tudur and Lip, Gregory Y H and Pettitt, Andrew R},
title = {A Comparative Analysis of Cardiovascular Events Associated With Acalabrutinib Versus Ibrutinib in Chronic Lymphocytic Leukemia: Insights From a Global Federated Network},
journal = {Pharmacology Research & Perspectives},
year = {2025},
doi = {10.1002/prp2.70113}
}
EUVIMED